Allergy Thera. Share News (AGY)
AGY Share
AGY Share
AGY Share
AGY Share
AGY
AGY Share
AGY Level 2
AGY Live
AGY Broker
AGY Directors
AGY Financial
AGY
AGY Short
AGY
Last checked at -
Thu, 29th Sep 2016 11:55
LONDON (Alliance News) - Allergy vaccines developer Allergy Therapeutics PLC said Thursday Chairman Peter Jensen bought 30,000 shares at a price of 19.25 pence per share on Wednesday.
Jensen now holds 150,000 shares.
The stock was up 2.3% at 19.70p Thursday.
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun
Copyright 2016 Alliance News Limited. All Rights Reserved.
EARNINGS UPDATES: Harbour Energy enters black; Fonix profit rises
Read moreIN BRIEF: Allergy Therapeutics cheers secondary endpoint results
Read moreIN BRIEF: Allergy Therapeutics study confirms peanut vaccine potential
Read more
(Sharecast News) - Pharmaceutical biotechnology company Allergy Therapeutics announced positive primary results from an ex-vivo biomarker study on Tuesday, evaluating its novel virus-like particle (VLP)-based peanut allergy vaccine candidate, VLP Peanut.
Read moreAllergy Therapeutics expects revenue rise in year despite challenges
Read moreTRADING UPDATES: Vitec and Allergy Therapeutics lift full-year outlook
Read more(Sharecast News) - Commercial biotechnology company Allergy Therapeutics said on Thursday that full-year operating profits were expected to be "well ahead" of market expectations thanks to "significantly lower" expenses.
Read moreTRADING UPDATES: Superdry optimistic; Virgin Wines toasts demand surge
Read more(Sharecast News) - Commercial biotechnology company Allergy Therapeutics announced the completion of the treatment of all patients in its 'G309' exploratory field study to evaluate the efficacy and safety of Grass MATA MPL in subjects with seasonal allergic rhinitis or rhinoconjunctivitis, induced by grass pollen.
Read moreTRADING UPDATES: Capita sells Irish unit; Daily Mail buys science mag
Read more(Sharecast News) - Commercial biotechnology company Allergy Therapeutics reported a 7% improvement in its revenue in actual terms in its interim results on Wednesday, and 5% growth at constant rate, to £54.0m.
Read moreIN BRIEF: Allergy Therapeutics Hails Growth; Non-Exec Smith To Leave
Read moreIN BRIEF: Allergy Therapeutics And Imperial Start Peanut Allergy Study
Read more(Sharecast News) - Speciality allergy-focussed pharmaceutical company Allergy Therapeutics announced on Tuesday that an ex-vivo biomarker study of blood samples from peanut allergy patients had started at Imperial College London.
Read moreIN BRIEF: Allergy Therapeutics Shareholders Revolt At General Meeting
Read more
Last checked at